DeepMed Research

Tianjin Medical University Cancer Institute & Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer

Not Applicable

Conditions: Gastric Cancer

Interventions: Procedure: Comparing Hyperthermic Intraperitoneal Chemotherapy
Drug: Paclitaxel
Drug: S1

First Posted Date: 2022-02-08

Last Posted Date: 2022-02-08

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 180

Registration Number: NCT05228743

Locations: 🇨🇳
Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China

Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

Phase 1

Conditions: Advanced Gastric Carcinoma
First-line Treatment

Interventions: Drug: Lenvatinib

First Posted Date: 2022-02-03

Last Posted Date: 2022-02-03

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 18

Registration Number: NCT05221775

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma

Not Applicable

Recruiting

Conditions: Cholangiocarcinoma

Interventions: Drug: GEMOX Regimen
Drug: Lenvatinib
Drug: Toripalimab

First Posted Date: 2022-01-31

Last Posted Date: 2024-12-11

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 146

Registration Number: NCT05215665

Locations: 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

Visualization Versus Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerves During Thoracoscopic Esophagectomy

Not Applicable

Conditions: Esophageal Cancer

Interventions: Procedure: intraoperative nerve monitoring

First Posted Date: 2022-01-20

Last Posted Date: 2022-06-01

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 120

Registration Number: NCT05199168

Locations: 🇨🇳
Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma

Phase 2

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Donafenib
Drug: Sintilimab
Other: HAIC

First Posted Date: 2021-12-22

Last Posted Date: 2021-12-22

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT05166772

H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study

Not Applicable

Conditions: Advanced HR+ HER2 Negative Breast Carcinoma

Interventions: Drug: Enituzumab injection+Abesili tablets+Anastrozole tablets

First Posted Date: 2021-12-22

Last Posted Date: 2022-04-07

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 40

Registration Number: NCT05167643

Locations: 🇨🇳
Tianjin Cancer Hospital, Tianjin, China

Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer

Phase 2

Recruiting

Conditions: Advanced HER2 Negative Breast Carcinoma
HRD+Breast Cancer

Interventions: Drug: fluzoparib+camrelizumab
Drug: fluzoparib+chidamide

First Posted Date: 2021-10-20

Last Posted Date: 2022-09-29

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 40

Registration Number: NCT05085626

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer

Phase 2

Recruiting

Conditions: Cervical Cancer

Interventions: Combination Product: Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy

First Posted Date: 2021-10-20

Last Posted Date: 2024-01-18

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 96

Registration Number: NCT05084677

Locations: 🇨🇳
Tianjin Medical University Cancer Institute&Hospital, Tianjin, Tianjin, China

Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC

Phase 2

Recruiting

Conditions: Advanced Colorectal Cancer
First-line Treatment

Interventions: Drug: Trifluridine/Tipiracil

First Posted Date: 2021-10-14

Last Posted Date: 2021-10-25

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 184

Registration Number: NCT05077839

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

A Study of OLR in First-line Treatment of Mantle Cell Lymphoma

Phase 2

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Orelabrutinib in in combination of rituximab and lenalidomide(OLR)

First Posted Date: 2021-10-13

Last Posted Date: 2021-11-11

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 29

Registration Number: NCT05076097

Locations: 🇨🇳
Tianjin Medical University Cancer Insititute & Hospital, Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy